Physician profile
Mark A Thompson
NPI 1265441729
$6,625.23
in general payments reported to CMS, 2019-2025
29 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,355 · 2022: $1,050 · 2023: $488 · 2024: $1,702 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,200 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,199.56 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,727.17 | 2021-2025 | Biktarvy, Epclusa |
| Viiv Healthcare Company | $1,623.57 | 2023-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $995.71 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $353.51 | 2021-2023 | Linzess |
| Glaxosmithkline, LLC. | $256.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $229.82 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.41 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $175.65 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.29 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.51 | 2021-2022 | |
| Novo Nordisk INC | $81.61 | 2021-2025 | Ozempic |
| Pfizer INC. | $61.87 | 2021 | |
| Emd Serono, INC. | $60.17 | 2025 | |
| Exact Sciences Corporation | $59.01 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $55.30 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals LP | $51.47 | 2021-2022 | |
| Janssen Biotech, INC. | $48.32 | 2023 | Symtuza |
| Hologic Sales and Service, LLC | $42.24 | 2025 | Thinprep 2000 Processor, Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $33.33 | 2022 | |
| Theratechnologies INC. | $33.03 | 2023-2024 | Egrifta Sv, Trogarzo, Egrifta |
| Amarin Pharma, INC. | $33.02 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.90 | 2021 | |
| Boston Scientific Corporation | $21.15 | 2024 | Wavewriter Alpha Prime 16 |
| Eisai INC. | $20.86 | 2022 | |
| Lilly USA, LLC | $14.43 | 2024 | Mounjaro |
| Aimmune Therapeutics, INC. | $14.38 | 2024 | |
| Nestle Healthcare Nutrition INC. | $11.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.